Treatment of latent tuberculosis infection: Update of guidelines, 2006;Tratamento da tuberculose latente: Revisão das normas, 2006

Revista Portuguesa de Pneumologia

Volumn 13, Issue 3, 2007, Pages 397-418

  Duarte, Raquel ^a   Amado, Joana ^b   Lucas, Helena ^b   Sapage, José Manuel ^b  

^a Sociedade Portuguesa de Pneumologia   (Portugal)

^b NONE

Author keywords

Chemoprophylaxis; Latent tuberculosis infection; Tracing; Treatment

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; BCG VACCINE; CORTICOSTEROID; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL; INDINAVIR; ISONIAZID; LEVOFLOXACIN; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PLACEBO; PREDNISOLONE; PROTEINASE INHIBITOR; PYRAZINAMIDE; PYRIDOXINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RIFAPENTINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; STREPTOMYCIN; UNINDEXED DRUG;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; LABORATORY DIAGNOSIS; LIVER INJURY; MYCOBACTERIUM TUBERCULOSIS; NEUROPATHY; PORTUGAL; PRACTICE GUIDELINE; STANDARDIZATION; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 34547411492     PISSN: 08732159     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0873-2159(15)30359-7     Document Type: Article

References (30)

1. Dados Estatísticos da Direcção Geral da Saúde. Programa Nacional de Luta contra a Tuberculose (PNT). Lisboa, Marco de 2003.
2. Gomes A, Carvalho JM, Gomes MC. Comissõ de Trabalho de Tuberculose da SPP. Tuberculinas. Rev Port Pneumol 1995; 1(3):229-39.
3. Lalvani A, Pathan AA, et al. Rapid Detection of Mycobacterium tuberculosis Infection by Enumeration of Antigen-specific T Cells. Am J Respir Crit Care Med 2001; 163:824-8.
4. Barnes PF. Diagnosing Latent Tuberculosis Infection. The 100-year Upgrade. Am J Respir Crit Care Med 2001; 163:807-8.
5. Centers for Disease Control and Prevention. Guidelines for Using the QuantiFERON-TB Test for Diagnosing Latent Mycobacterium tuberculosis Infection. MMWR 2003; 52(RR-02):15-8.
6. Neves Almeida F, Seabra MH, et al. Verificação da Alergia pós-vacinal por BCG. Utilização do Mantoux a 10 UT de PR 23. J Médico 1992; 123(2450): 360-2.
7. Thompson NJ, Glassroth JL, et al. The Booster Phenomenon in Serial Tuberculin Testing. Am Rev Resp Dis 1979; 119:587-97.
8. Villar M. Propostas Para a Interpretação e Utlização, no Dia a Dia, da Prova Tuberculínica. Edição em livro dos conteúdos disponibilizados em www.aidscongress.net entre 14/10/2002 e 29/11/2002, no III Congresso Virtual HIV/AIDS.
9. Pereira L, Marques L, et al. Diagnóstico e Tratamento da Tuberculose em Pediatria. Recomendações das Secções de Pneumologia e Infecciologia Pediátrica da Sociedade Portuguesa de Pediatria.
10. Rui Sarmento e Castro. Tuberculose em doentes infectados pelo vírus da imunodeficiência humana. Tese de Mestrado em Saúde Pública. 1999.
11. Centers for Disease Control and Prevention. Anergy skin testing and tuberculosis Preventive therapy for HIV-infected persons: revised recommendations. MMWR 1997; 46(NoRR-15):1-10.
12. Wang L, Turner MO, et al. A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements. Thorax 2002; 57:804-9.
13. Smith PG. BCG vaccination. In Clinical Tuberculosis Davies PO. Ed. Chapman and Hall Medical 1994:299-300.
14. Ninane J, Grymonprez A, et al. Disseminated BCG in HIV infection. Archives of Disease in Childhood 1998; 63:1268-9.
15. Lallement-Le Coeur S, Lallement M, et al. Bacillus Calmette-Guérin immunization in infants born to HIV-1 seropositive mothers. AIDS 1991; 5:195-9.
16. Msellati P. et al. BCG vaccination and pediatric HIV infection - Rwanda 1988-1990. Morbid. Mortal. Weekly Rep 1991; 40:833-6.
17. 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. http://www.aidsinfo.nih.gov.
18. Carvalho JM. Profilaxia da Tuberculose: O BCG e a Quimioprofilaxia. Edição em livro dos conteúdos disponibilizados em www.aidscongress.net entre14/10/2002 e 29/11/2002, no III Congresso Virtual HIV/AIDS.
19. Barreto C, et al. Tratamentos curtos em Taberculose infantil. Rev Port Pediatria 1989; 20:239-44.
20. American Thoracic Society, Centers for Disease Control and Prevention. Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. Am J Respir Crit Care Med 2001; 161 (Suppl): S221-47.
21. Cohn DL. Treatment of Latent Tuberculosis Infection: Renewed Opportunity for Tuberculosis Control. Clin Infect Dis 2000; 31:120-4.
22. Lecoeur HF, Truffot-Pernot C, Grosser JH. Experimental Short-course Preventive Therapy of Tuberculosis with Rifampin and Pyrazinamide. Am Rev Resp Dis 1989; 140:1189-93.
23. Stout JE, Engemann JJ, et al. Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis. Am J Respir Crit Care Med 2003; 167: 824-7.
24. Narita M, Kellman M, et al. Short-Course Rifamycin and Pyrazinamide Treatment for Latent Tuberculosis Infection in Patients with HIV Infection. Chest 2002; 122:1292-8.
25. Carvalho JM, Pamplona P. Normas para a Quimioprofilaxin da Tuberculose. Boletim da SPP 2000; no. 35.
26. Centers for Disease Control and Prevention. Updated Guidelines for the Use of Rifabutin or Rifampin for the Treatment and Prevention of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors. MMWR 2000; 49(No. 9):185-9.
27. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62.
28. Diniz A. Tuberculose e Infecção pelo VIH: o Tratamento. Edição em livro dos conteúdos disponibilizados em www.aidscongress.net entre 14/10/2002 e 29/11/2002, no III Congresso Virtual HIV/AIDS.
29. WorKing Group on Antiretroviral therapy:and Medical Management of Infants, Children and Adolescents with HIV Infection. Antiretroviral therapy and Medical Management of Pediatric HIV Infection. Pediatrics 1998;102(4):1005-1057.
30. WorKing Group on Antiretroviral therapy and Medical Managemment of HIV, Guidelines for the use of antiretroviral agents in Pediatric HIVinfection. 2001; (1-67).